Regarding the recent CNBC article https://www.cnbc.com/2021/07/24/large-shareho...todyn.html As many have already stated that FYI: The author Kenneth Squire is the manager of the 13D Activist Fund (DDDIX), which makes money by supporting 13D'd companies. Evidenced "Ken Squire - 13D Activist Fund https://www.linkedin.com › ken-squire-a58817b 13D Monitor and its online database, activistdatabase.com, is a comprehensive research and consulting service specializing in shareholder activism. Ken" ..
So you are correct that anytime a 13D popups up, it's in his best interest to praise it. As stated.."its not exactly unbiased article here. More like an advertisement." BUT THE ONE THING THAT THIS ARTICLE REPORTED CORRECTLY WAS "that leronlimab is an extraordinary drug" and "tremendous value will be created for the company's stockholders" so regardless of this recent manipulation our company will shine bright and true honesty, trust and faith in the science or win in the end. So I hope everyone continues to have a great weekend, and continue to look forward to a promising future.